August 17, 2015
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer

Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients

TOKYO, Japan, August 13, 2015 --- SymBio Pharmaceuticals limited (Headquarters: Tokyo, "SymBio") announced today that its U.S. partner, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova") has updated the status of its clinical trial for oral rigosertib in combination with azacitidine for the treatment of front-line and second-line higher risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukemia (AML), referred to as the 09-08 trial. According to Onconova, the Phase 2 trial is approaching full enrollment, and the company plans to present data from this study later this year.

The Phase 2 portion of the 09-08 trial is designed to assess whether treatment with rigosertib, in combination with azacitidine, reduces the number of bone marrow blasts, improves peripheral blood counts and delays signs of disease progression in patients with MDS and AML. To date, 33 patients (including 28 MDS patients) have received the recommended phase 2 dose in this study. Updated Phase 1 results and translational studies supporting the therapeutic rationale for the rigosertib/azacitidine combination were the subject of two presentations at the 13th International Symposium on Myelodysplastic Syndromes in the second quarter of 2015, demonstrating the tolerability and activity of the combination therapy in MDS and AML patients, including patients who had previously been treated with an HMA.

Both the IV formulation of rigosertib (SyB L-1101) in relapsed or refractory HR-MDS and oral formulation (SyB C-1101) of the drug in front-line lower risk transfusion dependent MDS/HR-MDS in combination with azacitidine are currently under preparation for clinical development by SymBio in Japan.

For more details on this press release, please visit Onconova's homepage at
http://investor.onconova.com/releases.cfm

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125

[1] BMCR assessed using International Working Group (IWG) and bone marrow blast (BMBL) criteria,